- Home
- BILI vs MDGL Comparison
BILI vs MDGL Comparison
Compare BILI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BILI | MDGL |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 10.0B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | BILI | MDGL |
|---|---|---|
| Price | $22.33 | $513.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $31.15 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.6M | 294.7K |
| Earning Date | 03-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $11.87 | $58.28 |
| Revenue Next Year | $9.51 | $46.80 |
| P/E Ratio | $122.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.47 | $265.00 |
| 52 Week High | $36.40 | $615.00 |
Technical Indicators
Market Signals| Indicator | BILI | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 31.07 | 70.14 |
| Support Level | $21.95 | $411.87 |
| Resistance Level | $25.67 | $610.00 |
| Average True Range (ATR) | 0.74 | 24.32 |
| MACD | -0.17 | 10.23 |
| Stochastic Oscillator | 3.07 | 61.84 |
Price Performance
Historical ComparisonAbout BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.